All Stories

  1. Analysis of the specificity of a COVID-19 antigen test in the Slovak mass testing program
  2. Analysis of the specificity of the SD Biosensor Standard Q Ag-Test based on Slovak mass testing data
  3. Are p-values Useful to Judge the Evidence Against the Null Hypotheses in Complex Clinical Trials? A Comment on ”The Role of p-values in Judging the Strength of Evidence and Realistic Replication Expectations”
  4. Statistical Challenges in the Conduct and Management of Ongoing Clinical Trials During the COVID-19 Pandemic
  5. Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology
  6. Analysis of Austrian COVID-19 deaths by age and sex
  7. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review
  8. A multiple comparison procedure for dose‐finding trials with subpopulations
  9. Quantitative approaches underpinning decision making
  10. Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17(5):593-606, Sep/Oct 2018., DOI:
  11. Nested combination tests with a time‐to‐event endpoint using a short‐term endpoint for design adaptations
  12. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency
  13. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
  14. Applicability and added value of novel methods to improve drug development in rare diseases
  15. Recent advances in methodology for clinical trials in small populations: the InSPiRe project
  16. Subgroup identification in clinical trials via the predicted individual treatment effect
  17. Design and estimation in clinical trials with subpopulation selection
  18. A proposal for a new PhD level curriculum on quantitative methods for drug development
  19. Methods for the analysis of multiple endpoints in small populations: A review
  20. Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup
  21. Statistical analysis of Goal Attainment Scaling endpoints in randomised trials
  22. Robustness of testing procedures for confirmatory subpopulation analyses based on a continuous biomarker
  23. Optimal exact tests for multiple binary endpoints
  24. Value of information methods to design a clinical trial in a small population to optimise a health economic utility function
  25. Marketing authorisation of orphan medicines in Europe from 2000 to 2013
  26. Approaches to sample size calculation for clinical trials in rare diseases
  27. Optimized adaptive enrichment designs
  28. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection
  29. Weekends affect mortality risk and chance of discharge in critically ill patients: a retrospective study in the Austrian registry for intensive care
  30. Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014)
  31. Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of
  32. “Threshold‐crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials?
  33. Estimation after blinded sample size reassessment
  34. Optimizing Trial Designs for Targeted Therapies
  35. Multi-arm group sequential designs with a simultaneous stopping rule
  36. Directions for new developments on statistical design and analysis of small population group trials
  37. Determination of the optimal sample size for a clinical trial accounting for the population size
  38. Preface
  39. Fallback tests for co-primary endpoints
  40. Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions
  41. Adaptive Designs for Clinical Trials with a Time to Event Endpoint
  42. Evidence, eminence and extrapolation
  43. Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels
  44. Preoperative abnormalities in serum sodium concentrations are associated with higher in-hospital mortality in patients undergoing major surgery
  45. Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review
  46. Decision-theoretic designs for small trials and pilot studies: A review
  47. Sample size reassessment for a two-stage design controlling the false discovery rate
  48. MCP2013 - 8th International Conference on Multiple Comparison Procedures
  49. Adaptive designs for subpopulation analysis optimizing utility functions
  50. Adaptive graph-based multiple testing procedures
  51. Flexible Designs
  52. Flexible Designs
  53. Bridging the gap: a review of dose investigations in paediatric investigation plans
  54. Connections between permutation andt-tests: relevance to adaptive methods
  55. Sharing clinical trial data on patient level: Opportunities and challenges
  56. Preoperative anaemia is associated with poor clinical outcome in non-cardiac surgery patients
  57. Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union
  58. Morphine Decreases Clopidogrel Concentrations and Effects
  59. Effect of intensive care after cardiac arrest on patient outcome: a database analysis
  60. Detection of epistatic effects with logic regression and a classical linear regression model
  61. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency
  62. Adaptive Budgets in Clinical Trials
  63. Simultaneous confidence intervals that are compatible with closed testing in adaptive designs
  64. Flexible Designs
  65. MCP2011-The 7th international conference on multiple comparison procedures
  66. Modeling and Simulation to Optimize the Design and Analysis of Confirmatory Trials, Characterize Risk-Benefit, and Support Label Claims
  67. Wideband UHF ISM-band transceiver supporting multichannel reception and DSSS modulation
  68. Gatekeepers and Enablers: How Drug Regulators Respond to a Challenging and Changing Environment by Moving Toward a Proactive Attitude
  69. Author's reply
  70. Bridging the gap: a review of dose-investigation studies in paediatric investigation plans
  71. Genome-wide CpG island methylation analyses in non-small cell lung cancer patients
  72. Unplanned adaptations before breaking the blind
  73. Nanoscalic silver possesses broad-spectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazine
  74. False discovery rate control in two-stage designs
  75. Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests
  76. Impact of dental implant length on early failure rates: a meta-analysis of observational studies
  77. Special Issue for Dealing with Multiplicity in Drug Development: Current State and New Directions – Guest Editors' Note
  78. Familywise Error Control in Multi-Armed Response-Adaptive Two-Stage Designs
  79. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim
  80. Cross-platform comparison of microarray data using order restricted inference
  81. Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study
  82. MCP2009 - 6th International Conference on Multiple Comparison Procedures
  83. Availability of Mental Health Service Providers and Suicide Rates in Austria: A Nationwide Study
  84. Availability of Mental Health Service Providers and Suicide Rates in Austria: A Nationwide Study
  85. Early postpartum hysterectomy: incidence and risk factors
  86. Skateboarding Injuries in Vienna: Location, Frequency, and Severity
  87. On the ropivacaine-reducing effect of low-dose sufentanil in intrathecal labor analgesia
  88. Post hoc power estimation in large-scale multiple testing problems
  89. Adaptive Designs and Confirmatory Hypothesis Testing
  90. Hunting for Significance With the False Discovery Rate
  91. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology
  92. Adaptive designs for confirmatory clinical trials
  93. T cell senescence and contraction of T cell repertoire diversity in patients with chronic obstructive pulmonary disease
  94. Optimal choice of the number of treatments to be included in a clinical trial
  95. A graphical approach to sequentially rejective multiple test procedures
  96. Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double-blind study
  97. Selection and bias-Two hostile brothers
  98. Diagnostic accuracy and reliability of muscle strength and endurance measurements in patients with chronic low back pain
  99. Correction
  100. Percutaneous ethanol instillation therapy for hepatocellular carcinoma – a randomized controlled trial
  101. MCP2007 - 5th International Conference on Multiple Comparison Procedures
  102. Optimized multi-stage designs controlling the false discovery or the family-wise error rate
  103. Exact Confidence Bounds Following Adaptive Group Sequential Tests
  104. A powerful multiple testing procedure improving the Bonferroni test
  105. A Note on repeated p-values for group sequential designs
  106. Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy
  107. Adaptive Dunnett tests for treatment selection
  108. Flexible Designs
  109. Vergleichende Analyse der Messwertergebnisse von zwei Dynamometern zur Messung der isokinetischen Kraft der kniegelenksbewegenden Muskulatur
  110. The scientific work of Peter Bauer
  111. Physiotherapy-Based Rehabilitation Following Disc Herniation Operation
  112. Effects of N-acetylcysteine against systemic and renal hemodynamic effects of endotoxin in healthy humans
  113. Elevated levels of interleukin-1?-converting enzyme and caspase-cleaved cytokeratin-18 in acute myocardial infarction
  114. Repeated confidence intervals for adaptive group sequential trials
  115. Flexible Designs
  116. Clinical Features, Classification and Prognosis of Migraine and Tension-Type Headache in Children and Adolescents: A Long-Term Follow-Up Study
  117. Diuretic potential of energy drinks
  118. On the efficiency of adaptive designs for flexible interim decisions in clinical trials
  119. Implant survival in mandibles of irradiated oral cancer patients
  120. Flexible Designs
  121. Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial Comparing Adjuvant Interferon Alfa and Isotretinoin With Interferon Alfa Alone in Stage IIA and IIB Melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group
  122. Attainability of boundary points under reinforcement learning
  123. Two-stage designs for experiments with a large number of hypotheses
  124. Übersetzung und psychometrische Austestung des Western-Ontario-Rotator-Cuff-Index (WORC) für den Gebrauch in deutscher Sprache
  125. Correlations between Self-Rated Fatigue with Quality of Life, and Social Participation in Viennese Outpatients Suffering from Advanced Cancer During Palliative Chemotherapy
  126. Übersetzung und psychometrische Austestung des Rotator Cuff Quality-of-Life Measure (RC-QOL) für den Gebrauch im deutschen Sprachraum
  127. Testing and estimation in flexible group sequential designs with adaptive treatment selection
  128. Long-term implant survival in the grafted maxilla: results of a 12-year retrospective study
  129. The German version of the Oxford shoulder score?cross-cultural adaptation and validation
  130. Conditional Rejection Probabilities of Student'st-test and Design Adaptations
  131. HSP-72 Expression in Pre-Transplant Donor Kidney Biopsies and Post-Transplant Outcome
  132. Rehabilitation of the severely atrophied maxilla by horseshoe Le Fort I osteotomy (HLFO)
  133. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections by H. Schäfer and H.-H. Müller,Statistics in Medicine 2001;20: 3741–3751
  134. Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy
  135. Muscle Fatigue and Fatigue-Related Biomechanical Changes During a Cyclic Lifting Task
  136. Sequential Tests for Noninferiority and Superiority
  137. Factors That Influence the Duration of Splint Wear in Peripheral Nerve Lesions
  138. Impact of Pneumococcal Vaccination on Morbidity and Mortality of Geriatric Patients: A Case-Controlled Study
  139. Issues in designing flexible trials
  140. Statistical Methods for Clinical Trials. M. X. Norleans, Marcel Dekker, New York, 2001. No. of pages: 257. ISBN 0-8247-0467-3
  141. Recursive Combination Tests
  142. Short segment stimulation of the anterior transposed ulnar nerve at the elbow
  143. Multiple Testing for Identifying Effective and Safe Treatments
  145. Interim Analysis and Sample Size Reassessment
  146. Load-dependence of fatigue related changes in tremor around 10 Hz
  147. Adaptive Two Stage Designs and the Conditional Error Function
  148. The efficiency of adapting aspiration levels
  149. Win–Stay, Lose–Shift Strategies for Repeated Games—Memory Length, Aspiration Levels and Noise
  150. Cycling in a stochastic learning algorithm for normal form games